To validate the therapeutic feasibility of MCL1 inhibition in ccRCC, we sought to investigate PRT1419 in a cell-line derived xenograft (CDX) model of PBRM1-mutant ccRCC. Here, PBRM1 is linked to nonpapillary renal cell carcinoma.